Clinical Trials Browser

Active not recruiting × Neuroendocrine Tumors × Bevacizumab × Clear all

NCT00569127 2026-05-29

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

Phase 3 Active not recruiting

427 enrolled 17 charts

Neuroendocrine Tumors